Full Text
PDB27 A COST-UTILITY ANALYSIS OF ORLISTAT (XENICAL®) IN THE TREATMENT OF DIABETIC PATIENTS WITH MORBID OBESITY AND ADDITIONAL CVD RISK IN NORWAY

Abstract

Authors

JM Sverre FKO Kristensen LB Holm K Nyhus

Back to Volume 9, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×